Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
10.39
+0.34 (3.38%)
At close: Mar 9, 2026, 4:00 PM EDT
10.37
-0.02 (-0.19%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
591.85M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDSGN News
- 3 hours ago - Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 19 days ago - Design Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - Design Therapeutics Appoints Justin Gover to Board of Directors - GlobeNewsWire
- 6 months ago - Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 months ago - Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference - GlobeNewsWire
- 7 months ago - Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 9 months ago - Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 - GlobeNewsWire